AMLX - Amylyx Pharmaceuticals, Inc.

QQQ $ 452.00 $ 6.14 (1.38 %)

DIA $ 398.69 $ 0.81 (0.2 %)

SPY $ 528.77 $ 5.47 (1.05 %)

TLT $ 92.22 $ 1.36 (1.5 %)

GLD $ 221.08 $ 1.85 (0.84 %)

Previous Close

$ 1.87

Open

$ 1.89

Bid

$ 1.88 x 472

Ask

$ 1.91 x 202

Day's Range

$ 1.88 - $ 1.93

52 Week Range

$ 1.70 - $ 29.24

Volume

1,572,136

Average Volume

Market Cap

126.89M

Beta (5Y Monthly)

$ 0.93

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	05-09-2024	03-31-2024	10-Q
2	02-22-2024	12-31-2023	10-K
3	11-09-2023	09-30-2023	10-Q
4	08-10-2023	06-30-2023	10-Q
5	05-11-2023	03-31-2023	10-Q
6	03-13-2023	12-31-2022	10-K
7	11-10-2022	09-30-2022	10-Q
8	08-11-2022	06-30-2022	10-Q
9	05-12-2022	03-31-2022	10-Q
10	03-31-2022	12-31-2021	10-K

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

Mizuho Maintains Neutral on Amylyx Pharma,...
05/14/2024 10:47:43

Mizuho analyst Graig Suvannavejh maintains Amylyx Pharma (NASDAQ:AMLX) with a Neutral and lowers the price target from $4 to...

Breaking Down Amylyx Pharma: 9 Analysts Sh...
05/10/2024 18:01:12

HC Wainwright & Co. Reiterates Buy on Amyl...
05/10/2024 12:25:27

HC Wainwright & Co. analyst Andrew Fein reiterates Amylyx Pharma (NASDAQ:AMLX) with a Buy and maintains $8 price target.

Amylyx Pharma Cash, Cash Equivalents And ...
05/09/2024 12:04:14

Amylyx Pharma Q1 2024 GAAP EPS $(1.75)May ...
05/09/2024 12:03:33

Baird Maintains Neutral on Amylyx Pharma, ...
04/11/2024 10:43:32

Baird analyst Joel Beatty maintains Amylyx Pharma (NASDAQ:AMLX) with a Neutral and lowers the price target from $4 to $3.

HC Wainwright & Co. Reiterates Buy on Amyl...
04/11/2024 10:29:38

HC Wainwright & Co. analyst Andrew Fein reiterates Amylyx Pharma (NASDAQ:AMLX) with a Buy and maintains $8 price target.

amylyx-pharmaceuticals-investigational-drug-shows-improved-pancreatic-function-in-patients-with-inherited-disorder

Amylyx Pharmaceuticals' Investigational Dr...
04/10/2024 17:14:44

Amylyx's AMX0035 data in treating Wolfram syndrome, with interim data indicating positive effects on diabetes progression, ...

Amylyx Pharmaceuticals Announces Interim D...
04/10/2024 13:02:32

- Interim analysis, including eight participants assessed at Week 24, demonstrated improvements in pancreatic function and glyc...

Amylyx Pharmaceuticals To Host Virtual Web...
04/08/2024 13:01:44

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) ("Amylyx" or the "Company") today announced the Company will host a ...

Unveiling 6 Analyst Insights On Amylyx Pharma
04/08/2024 12:00:22

HC Wainwright & Co. Maintains Buy on Amyly...
04/08/2024 11:11:56

HC Wainwright & Co. analyst Andrew Fein maintains Amylyx Pharma (NASDAQ:AMLX) with a Buy and maintains $8 price target.

Amylyx Pharmaceuticals To Advance AMX0035 ...
04/04/2024 11:18:47

Amylyx Pharmaceuticals Will Reduce Its Wor...
04/04/2024 11:16:59

Amylyx Pharmaceuticals Announces Formal In...
04/04/2024 11:16:01

Relyvrio/Albrioza will no longer be available for new patients as of today; Patients currently on therapy in the U.S. and Canad...

cns-disorder-focused-seelos-therapeutics-plunges-to-52-week-low---heres-why

CNS Disorder-Focused Seelos Therapeutics P...
03/19/2024 13:38:47

Seelos Therapeutics updates Phase 2/3 HEALEY ALS trial with SLS-005, showing potential efficacy in subgroup analysis. Explore t...

HC Wainwright & Co. Maintains Buy on Amyly...
03/12/2024 10:43:22

HC Wainwright & Co. analyst Andrew Fein maintains Amylyx Pharma (NASDAQ:AMLX) with a Buy and lowers the price target fro...

Goldman Sachs Downgrades Amylyx Pharma to ...
03/11/2024 13:22:07

Goldman Sachs analyst Chris Shibutani downgrades Amylyx Pharma (NASDAQ:AMLX) from Buy to Neutral and lowers the price target...

Leerink Partners Downgrades Amylyx Pharma ...
03/11/2024 12:13:14

Leerink Partners analyst Marc Goodman downgrades Amylyx Pharma (NASDAQ:AMLX) from Outperform to Market Perform.

Baird Downgrades Amylyx Pharma to Neutral,...
03/11/2024 12:11:02

Baird analyst Joel Beatty downgrades Amylyx Pharma (NASDAQ:AMLX) from Outperform to Neutral and lowers the price target from...